This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01928771
First received: August 16, 2013
Last updated: March 23, 2017
Last verified: March 2017
  Purpose
The purpose of this study is to determine whether Benralizumab reduces the number of asthma exacerbations in patients who remain uncontrolled on high doses of ICS-LABA.

Condition Intervention Phase
Asthma Biological: Benralizumab Biological: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils >=300/uL [ Time Frame: Immediately following the first administration of study drug through Study Week 48. ]
    The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF


Secondary Outcome Measures:
  • Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils < 300/uL [ Time Frame: Immediately following the first administration of study drug through Study Week 48. ]
    The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF

  • Annual Asthma Exacerbation Rate Resulting Emergency Room Visits and Hospitalizations [ Time Frame: Immediately following the first administration of study drug through Study Week 48. ]
    The annual exacerbation rate associated with an emergency room visit or a hospitalization (adjudicated)

  • Number of Patients With >=1 Asthma Exacerbations [ Time Frame: Immediately following the first administration of study drug through Study Week 48. ]
  • Time to First Asthma Exacerbation [ Time Frame: Immediately following the first administration of study drug through Study Week 48. ]
  • Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils >=300/uL [ Time Frame: Immediately following the first administration of study drug through Study Week 48. ]
  • Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils <300/uL [ Time Frame: Immediately following the first administration of study drug through Study Week 48. ]
  • Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils >=300/uL [ Time Frame: Immediately following the first administration of study drug through Study Week 48. ]
    Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.

  • Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils <300/uL [ Time Frame: Immediately following the first administration of study drug through Study Week 48. ]
    Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.

  • Change in Asthma Rescue Medication [ Time Frame: Immediately following the first administration of study drug through Study Week 48. ]
    Change from baseline to week 48 in number of rescue medication use (puffs/day)

  • Home Lung Function Assessment Based on Morning PEF [ Time Frame: Immediately following the first administration of study drug through Study Week 48. ]
    Change from baseline to week 48 in home lung function morning peak expiratory flow [PEF]

  • Home Lung Function Assessment Based on Evening PEF [ Time Frame: Immediately following the first administration of study drug through Study Week 48. ]
    Change from baseline to week 48 in home lung function evening peak expiratory flow [PEF]

  • Proportion of Night Awakening Due to Asthma [ Time Frame: Immediately following the first administration of study drug through Study Week 48. ]
    Change from baseline to Week 48 on proportion of night awakening due to asthma

  • Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils >=300/uL [ Time Frame: Immediately following the first administration of study drug through Study Week 48. ]
    ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of <=0.75 indicates well-controlled asthma, scores between 0.75 to <=1.5 indicate partly controlled asthma, and >1.5 indicates not well controlled asthma.

  • Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils <300/uL [ Time Frame: Immediately following the first administration of study drug through Study Week 48. ]
    ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of <=0.75 indicates well-controlled asthma, scores between 0.75 to <=1.5 indicate partly controlled asthma, and >1.5 indicates not well controlled asthma.

  • Pharmacokinetics of Benralizumab [ Time Frame: Baseline, week 4, week 4 day 6, week 8, week 16, week 24, week 32, week 40, week 48, week 56 ]
    Mean PK concentrations at each visit

  • Immunogenicity of Benralizumab [ Time Frame: Pre-treatment until end of follow-up ]
    Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at >=2 post baseline assessments (with >=16 weeks between the first and the last positive) or positive at last post baseline assessment. Transiently positive is defined as having at least one post baseline ADA positive assessment and not fulfilling the conditions of persistently positive.

  • Extend of Exposure [ Time Frame: Immediately following the first administration of study drug through Study Week 48. ]
    Extend of exposure is defined as duration of treatment in days

  • Mean Change From Baseline to Week 48 in AQLQ(S)+12 [ Time Frame: Immediately following the first administration of study drug through Study Week 48. ]
    AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of >=0.5 are considered clinically meaningful.

  • Mean Change From Baseline to Week 48 in EQ-5D-5L VAS [ Time Frame: Immediately following the first administration of study drug through Study Week 48. ]
    EQ-5D-5L VAS is to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.

  • Mean Work Productivity Loss Due to Asthma [ Time Frame: Immediately following the first administration of study drug through Study Week 48. ]
    WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked. The work productivity loss is only applicable to patients who employed, which is only subset of the study population.

  • Mean Productivity Loss Due to Asthma in Classroom [ Time Frame: Immediately following the first administration of study drug through Study Week 48. ]
    WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Classroom productivity loss is derived by sum of percentage of missed classes due to asthma and product of percentage of actual hours attending classes times degree of asthma affecting classroom productivity. Percentage of missed classes due to asthma is calculated by number of hours missed classes due to asthma divided by total number of hours missed classes plus number of hours actually attending classes. This is only applicable to patients who attending classes

  • Number of Participants That Utilized Health Care Resources [ Time Frame: Immediately following the first administration of study drug through Study Week 48. ]
  • Patient and Clinician's Responder Assessment to Treatment [ Time Frame: Immediately following the first administration of study drug through Study Week 48 ]
    CGIC (Clinical global impression of change), and PGIC (Patient global impression of change) are overall evaluation of response to treatment, conducted separately by investigator and patient using 7-point rating scale, ranging from 1 (very much improved), to 7 (very much worse). This is additional measures collected after second Amendment, thus not all patients had data to be analyzed.


Enrollment: 2681
Study Start Date: September 19, 2013
Study Completion Date: April 5, 2016
Primary Completion Date: April 5, 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Benralizumab 30 mg q.4 weeks
Benralizumab administered subcutaneously every 4 weeks
Biological: Benralizumab
Benralizumab subcutaneously on study week 0 until study week 44 inclusive.
Experimental: Benralizumab 30 mg q.8 weeks
Benralizumab administered subcutaneously every 8 weeks
Biological: Benralizumab
Benralizumab subcutaneously on study week 0 until study week 44 inclusive.
Placebo Comparator: Placebo
Placebo administered subcutaneously
Biological: Placebo
Placebo subcutaneously on study week 0 until study week 44 inclusive.

  Eligibility

Ages Eligible for Study:   12 Years to 75 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written informed consent for study participation must be obtained prior to any study related procedures being performed (local regulations are to be followed in determining the assent/consent requirements for children and parent[s]/guardian[s]) and according to international guidelines and/or applicable European Union guidelines.
  2. Female and Male aged 12 to 75 years inclusively, at the time of visit 1. For those patients, who are 17 on the day of Visit 1 but will turn 18 after this day, will be considered an adolescent for the purposes of this trial.
  3. History of physician-diagnosed asthma requiring treatment with medium-to-high dose ICS (>250μg fluticasone dry powder formulation equivalents total daily dose) and a LABA, for at least 12 months prior to Visit 1
  4. Documented treatment with ICS and LABA for at least 3 months prior to Visit 1 with or without oral corticosteroids and additional asthma controllers.

    • For subjects 18 years of age and older, the ICS dose must be >500 mcg/day fluticasone propionate dry powder formulation or equivalent daily.
    • For subjects ages 12-17, the ICS dose must be ≥500 mcg /day fluticasone propionate dry powder formulation or equivalent daily.

Exclusion criteria:

  1. Clinically important pulmonary disease other than asthma (e.g. active lung infection, COPD, bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (e.g. allergic bronchopulmonary aspergillosis/mycosis, Churg- Strauss syndrome, hypereosinophilic syndrome)
  2. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:

    • Affect the safety of the patient throughout the study
    • Influence the findings of the studies or their interpretations
    • Impede the patient's ability to complete the entire duration of study
  3. Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date informed consent is obtained or during the screening/run-in period
  4. Any clinically significant abnormal findings in physical examination, vital signs, haematology, clinical chemistry, or urinalysis during screening/run-in period, which in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01928771

  Show 281 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Eugene R. Bleecker, MD, Professor of Medicine Center for Genomics and Personalized Medicine Research, Medical Center Boulevard, Winston-Salem, North Carolina 27157
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01928771     History of Changes
Other Study ID Numbers: D3250C00017
Study First Received: August 16, 2013
Results First Received: September 28, 2016
Last Updated: March 23, 2017

Keywords provided by AstraZeneca:
Asthma,
Bronchial Diseases,
Respiratory Tract Diseases,
Lung Diseases,
Obstructive Lung Diseases

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on September 21, 2017